Welcome to the Working Group on New TB Drugs Blog
This Week in TB R&D – 24 August 2010
Last week, a paper was published in Nature by Matthew Berry, Christine Graham et al. which received a fair amount of notice. The authors presented data identifying a probable TB gene signature in people infected with TB.
Initially the investigators examined genome-wide transcriptional profiles generated from RNA extracted from whole blood, purified neutrophils, monocytes, and [...]
TB Alliance: New Potential TB Drugs to be Investigated Against Multiple Neglected Diseases
New York, United States and Geneva, Switzerland — July 7, 2010 The TB Alliance and Drugs for Neglected Diseases Initiative (DNDi) announced today a unique first-ever royalty-free license agreement between two not-for-profit drug developers that speeds progress toward markedly improved therapy of multiple neglected diseases.
Impact of the CPTR Initiative
After a decades-long drought, new pharmaceutical discoveries and repurposing of existing antimicrobials have produced about 10 drugs from 7 different classes which are now in various stages of clinical development for TB.
Launch of the Critical Path to TB Drug Regimens
Today marks the launch of an exciting new initiative in TB R&D. The US Food and Drug Administration (FDA) has supported the Critical Path to TB Drug Regimens (CPTR). The CPTR comprises a broad collaborative network of partners including pharmaceutical companies, government, academia, and advocates, and NGOs with the focus to accelerate the development of new, safe, and highly effective shorter length TB treatment regimens.
The Week in TB R&D – March 9, 2010
The WGND blog is in the R&D vanguard! Recently, Nick Be wrote a post highlighting the activation of the cellular ‘self-eating’ mechanism known as autophagy in the elimination of TB from an infected individual. On March 5, 2010, Cell published a paper by Kumar and colleagues, which further supports the hypothesis that M. tb [...]
Interview with Pere Joan Cardona
For 15 years, Dr. Cardona has focused his studies on infection with Mycobacterium tuberculosis (Mtb) has developed a hypothesis and dynamics of tuberculosis infection, which could explain why the Koch bacillus persists in the human body as implies a continuous reinfection of tissues. This may open the field to new health tools that provide an adequate response to the challenges of this ancient disease that kills 1.8 million people each year.
Vitamins, Sunshine and Cannibalism: New Partners in the Fight to Stop Tuberculosis
One of the characteristics making M. tuberculosis such an insidious killer is its uncanny ability to thwart many of our best defenses. Whether through hiding itself in our lungs for years or escaping our efforts at treatment through multi-drug resistance, this bug often acts as an exceptional escape artist.
-
Toppix TB News- Isoniazid resistance and death in patients with tuberculous meningitis: retrospective cohort study. 8 Sep 2010
- Global Fund needs U.S. support 8 Sep 2010
- New park memorializes ORC 7 Sep 2010
- Experimental TB test called fast, accurate 7 Sep 2010
- People with diabetes up to 2-3 times higher risk of TB 7 Sep 2010
